“Merck and Moderna Explore Expanding Cancer Vaccine Partnership After Early Success” — what this page in the network covers. Merck and Moderna are considering broader applications for their personalized mRNA cancer vaccine following promising early results, executives Stephen Hoge and Dean Li revealed at the STAT Summit. The collaboration pairs Moderna's mRNA technology with Merck's blockbuster immunotherapy Keytruda to target tumors. Initial data showed the combination reduced the risk of recurrence or death by 44% in melanoma patients compared to Keytruda alone, a significant step for personalized cancer treatment.
The companies are now exploring the vaccine's potential in other tumor types and settings, including earlier-stage disease, where the immune system may be more responsive. This partnership combines two powerful platforms—Merck's checkpoint inhibitor and Moderna's customizable mRNA—to create a therapy tailored to each patient's unique cancer mutations. This listing links straight to the original page, where the content is available in full.